Australian Federation of AIDS Organisations (AFAO), 23 August, 2016
Following the Pharmaceutical Benefits Advisory Committee (PBAC) decision not to recommend funding PrEP through the Pharmaceutical Benifits Scheme (PBS), AFAO has produced an Australian PrEP roundup paper to sustain advocacy efforts and to raise awareness about current options for accessing PrEP around the country.
In releasing their decision, the PBAC has said they accept the importance of PrEP but were unable to recommend it for a number of reasons, including the cost-effectiveness of the price submitted by Gilead Sciences.
Despite this setback, AFAO will continue with community advocacy to have Gilead Sciences resubmit its application as soon as possible. Interim PrEP access arrangements remain crucial in the meantime.